CJC-1295 without DAC and with DAC: differences in structure and in studies

Summary in a few words

CJC-1295: a GHRH analogue that enhances pulsatile GH secretions and increases IGF-1. Two forms: without DAC (Mod GRF(1–29)) – short-acting, closer to physiology, often with Ipamorelin; and with DAC – prolonged action through binding to albumin, offering consistently higher IGF-1 but with a greater risk of non-pulsatile stimulation & fluid retention.

What CJC-1295 is in brief

GHRH: a hypothalamic peptide that activates the somatotrophs of the pituitary and causes a GH pulse; the GH increase leads to IGF-1 and anabolic effects (protein synthesis, remodelling, bone metabolism).

• Without DAC (Mod GRF(1–29)): tetra-substituted segment 1–29, more resistant to breakdown; t1/2 short (tens of minutes to ~1–2 hours).
• With DAC: includes the Drug Affinity Complex, which binds to albumin and prolongs circulation to days (steady ↑IGF-1).

The critical difference – short pulse vs. prolonged exposure – determines the practical scenarios.

Why pulsatility matters

Endogenous GH is secreted in waves (mainly at night, linked to slow-wave sleep). Short, synchronised stimulation is often associated with better sleep/recovery at a moderate ↑IGF-1, while prolonged exposure may bring more intense but less controllable metabolic effects. See a review on GH pulsatility (PubMed).

Pharmacokinetics & example dosing (research context)

• Without DAC: short action → 1–3 times/day, often in the evening; rationale – enhancement of nocturnal GH pulses. Synergy with Ipamorelin (GHS-R agonist).
• With DAC: prolonged action → 1–2 times/week; steady ↑IGF-1, but less control of timing and a higher likelihood of fluid retention/headache.

Benefits: where they coincide and where they differ

Common possible benefits (“recovery & anabolism” category)

• Better slow-wave sleep and subjective recovery.
• Collagen remodelling & support of connective tissue (GH → IGF-1).
• Improvement of body composition with controlled nutrition/exercise.
• Support of muscle protein synthesis with adequate protein intake.

Particularities of CJC-1295 without DAC

Advantages More “physiological” pulsatility, fine adjustment of dose, good evening synchronisation; often less fluid retention; excellent synergy with Ipamorelin.

Disadvantages More frequent administration; depends on sleep hygiene/nutrition.

Particularities of CJC-1295 with DAC

Advantages Convenience (infrequent dosing), steady ↑IGF-1 (days), possibly a stronger anabolic background.

Disadvantages Greater risk of non-pulsatile stimulation and fluid retention/headache; harder control of timing; caution regarding glycaemic control.

What the literature shows (in brief)

• For CJC-1295 with DAC in humans: prolonged ↑IGF-1 for 1–2 weeks after the dose; local reactions and transient fluid retention (PubMed).
• For Mod GRF(1–29) / without DAC: short GH peaks, a more controllable profile; synergy with selective GHS-R agonists such as Ipamorelin – low effect on ACTH/cortisol.
• Reviews of GH pulsatility stress the physiological rhythm for sleep/recovery (review).
• Metabolic targeting of visceral fat: tesamorelin with RCT data.

When each version is used (research rationale)

• Sleep & recovery: without DAC, evening synchronisation, often in combination with Ipamorelin.
• More stable anabolic background / IGF-1: with DAC, but with stricter monitoring for oedema/headache/glucose.
• Body composition with a metabolic emphasis: Tesamorelin ± Ipamorelin; CJC with DAC can offer an IGF-1 background, but is not the only option.
• Redox “shield” under high exercise load: Glutathione as a background against oxidative stress.

Combinations

When they are NOT used / warnings

• Active or unclarified neoplasms.
• Uncontrolled hyperglycaemia/insulin resistance, severe oedema/heart disease.
• Pregnancy/lactation; minors.
• Anti-doping: GH secretagogues are on the WADA list – athletes must avoid them.
• Allergies/hypersensitivity to excipients/solvents.

Practical notes (logistics & safety)

• Lyophilised vs. liquid solutions: in the absence of public stability data for ready-made liquids, the dry form is more conservative. See the detailed article.
• Timing: without DAC – often evening; with DAC – weekly schedule, less “fine” alignment with sleep.
• Monitoring: subjective markers (sleep, oedema, headache), IGF-1; glucose/lipids in vulnerable people, BP.
• Nutrition/protein: GH signal without sufficient protein/energy intake → limited results.

Which is “the best”?

There is no “winner for everyone” – it depends on goal & risk: for fine, “physiological” support of sleep/recovery → without DAC (+ Ipamorelin). For a steady IGF-1 background with acceptance of stricter monitoring → with DAC. For a metabolic goal (visceral fat) see Tesamorelin. Under high exercise load add Glutathione for redox balance.

See the “Recovery and anabolic peptides” category Ask a question

Sources

1. Teichman SL et al. – “CJC-1295, a long-acting GHRH analog”.
2. Raun K. et al. – “Ipamorelin, the first selective GH secretagogue”.
3. Veldhuis JD, Bowers CY – review of GH pulsatility & GHRH/ghrelin physiology.
4. Falutz J. et al. – Tesamorelin & visceral fat (RCT).
5. Review of glutathione & muscle recovery (redox, PMC).
6. WADA – Prohibited List (GH & secretagogues).
7. Peptology – Lyophilised vs. pre-mixed: stability & logistics.